Certainly, a fatal complication of severe acute respiratory syndrome coronavirus through infection is venous thromboembolism. Thromboprophylaxis should be balanced against the risk of bleeding, and hence a  study examined the risk of VTE and major bleeding in coronavirus 2 patients. Researchers used nationwide population-based registries, the reports of coronavirus to positive patients were compared to those of the negative patients to check the 30-day risks of VTE. All the medical records of corona patients but investigated in detail in Denmark. The all-inclusive 30-day risk of VE was 0.4% (40/9460) among SARS-CoV-2 patients (16% hospitalized), 0.3% (649/226 510) among Coronavirus 2 patients negative subjects that is (12% hospitalize), 1% between the influenza patients that is 59% hospitalized the VTE risks in hospitalized coronavirus 2 positive was 1.5% coronavirus two negative was 1.8%. Influenza patients came out to be 1.5% which was comparably very high. Major bleeding was diagnosed in 0.5% of all coronavirus 2 positive individuals, out of which 2.3% were hospitalized. The analysis of medical records concluded that 582 hospitalized coronavirus 2 patients word tested for VTE in 4%, that is 19 out of 450, and major bleeding was reported in 0.4%, that is two out of 450 of the ward patients. Out of the researched data, only 31% got thromboprophylaxis. VTE risks went from low to average in coronavirus 2 infection in a population-based setting compared with coronavirus 2 test negative and influenza patients. Bleeding risks were low for ward patients, but VTE risk in ICU was more.